Subscribe to this RSS feed

Newsletter

Clinuvel's regular newsletter, Clinuvel Communiqué, including archives.

Clinuvel Newsletter - April 2012

03 Apr 2012

Clinuvel Newsletter - February 2012

29 Feb 2012

Clinuvel Newsletter - October 2011

14 Oct 2011
| CEO’s Outlook | Dossier preparation for SCENESSE® | INSPIRE vitiligo program update | Media coverage | Share price & financials | Summary of the SCENESSE® pipeline

Clinuvel Newsletter - May 2011

25 May 2011
| CEO’s Overview | Confirmatory EPP studies complete in the US & Europe | INSPIRE vitiligo program update | Guest bloggers and new video releases | Share price and financials

Clinuvel Newsletter - January 2011

10 Jan 2011
| CEO’s Outlook | ASCEM III (Luzern 23-24 January 2011) | Share consolidation – CUV/CLVLY | CUV holders: are your details up to date? | Share price and financials | Expected clinical results timeline 2011

Clinuvel Newsletter - November 2010

22 Nov 2010
| CEO’s Outlook | New research into photosensitive diseases and quality of life | Clinuvel’s new program: nonsegmental vitiligo | Share price and financials | 2010 Annual General Meeting

Clinuvel Newsletter - August 2010

23 Aug 2010
| CEO’s Outlook | US patent grant for UV protection | SCENESSE® unveiled as approved drug name | Share price and financials | A world first: SCENESSE® now available by prescription to Italian EPP patients | Clinuvel’s global clinical program

Clinuvel Newsletter - May 2010

07 May 2010
| CEO’s Outlook | US porphyria awareness week | Clinical and regulatory timeline | Life with EPP: guest blogger series | Share price and financials | European update: Clinuvel’s regulatory program focus - EPP | Clinuvel New Media Site

Clinuvel Newsletter - March 2008

31 Mar 2008
Clinuvel Newsletter - March 2008

Clinuvel Newsletter - July 2008

01 Jul 2008
Clinuvel Newsletter - July 2008
Page 1 of 2

Investors' Blog Posts

Delivering a therapy for those who need it most: EPP...

Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...

Read More

MAA: a moment in Clinuvel’s EPP story...

Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the company announced its first...

Read More

Online evolution...

Earlier this week we unveiled a major update to our online presence with the release of our new-look website and the launch of Mothers...

Read More

Investor Spotlight

Annual Report for the year ended 30 June 2011

Contents: INTRODUCTION ERYTHROPOIETIC PROTOPORPHYRIA (EPP) NONSEGMENTAL VITILIGO (NSV) CLINUVEL BUSINESS MODEL CORPORATE MILESTONES CHAIR's LETTER MANAGING DIRECTOR’S REPORT FINANCIALS ADDITIONAL INFORMATION REQUIRED BY THE ASX MARKET PERFORMANCE GLOSSARY ...

Read more

Related Webcasts

Understanding Vitiligo: Misconception & Myth...

Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,...

Watch now

'Check up' reports on rare disease EPP and SCENESSE...

On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab...

Watch now

"Focus really pays off in the end"...

Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic...

Watch now